Side effects of Wegovy 0.25mg: what your body is adjusting to

Your first week on 0.25mg: what the body is usually doing

Picture the scene: the pen is in the fridge, you've done your first injection, and by day three you notice your appetite has dipped and your stomach feels a little unsettled. This is the most typical opening chapter of semaglutide treatment. GLP-1 receptor agonists slow the rate at which the stomach empties, and that change alone can produce nausea, a sense of fullness that arrives early in a meal, and occasionally burping or reflux. At 0.25mg, the signal to the gut is relatively gentle, which is precisely why Novo Nordisk and the prescribing guidance start everyone here.

The side effects most commonly reported at this dose are nausea, diarrhoea or loose stools, constipation, and mild headache. Fatigue crops up for some people too, often in the first few days. For the majority, these settle considerably within two to four weeks. Small, lower-fat meals, good hydration and giving yourself time to eat without rushing all help. Our prescribers hear most weeks that patients expected worse, which is reassuring, though everyone's experience is individual.

Injection-site reactions (redness, mild swelling or itching at the spot where you injected) are also possible. Rotating between the abdomen, thigh and upper arm across doses reduces the chance of localised irritation. The NHS semaglutide guidance lists the full range of reported reactions by frequency, and the Patient Information Leaflet that comes with your pen is the definitive reference for what has been observed across the clinical programme.

Wegovy 0.25mg side effects that need the same-day attention of a doctor

Most symptoms at 0.25mg are uncomfortable rather than dangerous. A few are not. It matters to know the difference before you need to.

Pancreatitis is an infrequent but serious risk with GLP-1 medicines. In January 2026 the MHRA issued a Drug Safety Update specifically noting acute pancreatitis in people taking this class of medicines. The symptom to act on immediately is severe, persistent pain in the upper abdomen that may spread towards the back, particularly if vomiting accompanies it. This is not ordinary nausea, it is distinct and does not ease. Stop eating and seek urgent medical help. Do not wait to see if it improves.

An allergic reaction to semaglutide is rare but possible: swelling of the face, lips or throat, difficulty swallowing or breathing, and a rapid heartbeat are signs to call 999 or get to an emergency department without delay. Similarly, if prolonged vomiting or diarrhoea is causing signs of dehydration (dizziness on standing, very little urine, confusion) contact a healthcare professional the same day rather than managing at home. Kidney function can be affected by severe dehydration in people on GLP-1 treatment. You can read more about how the broader dose journey tends to progress on our page covering the transition from 0.25mg to 0.5mg.

How 0.25mg fits into the full Wegovy dose schedule

The 0.25mg dose sits at the very beginning of the Wegovy titration pathway. It is not where the weight-management effect is strongest; its job is to give your body a chance to get used to semaglutide before the dose climbs. After roughly four weeks, a prescriber will typically move treatment to 0.5mg, then 1mg, 1.7mg and, for many people, the 2.4mg maintenance dose, where our page on Wegovy 2.4 side effects explains what people commonly encounter at that stage. Some patients are now eligible for 7.2mg, which the MHRA approved in early 2026.

Side effects often intensify slightly at each upward step, then settle again. That pattern is worth knowing now: a little nausea returning after a dose increase is usually a repeat of what happened at 0.25mg, not a sign that something has gone wrong. Our pages on the 0.5mg side-effect profile and the 1mg stage describe what people tend to experience at each level. If you want to see the full schedule laid out in one place, the Wegovy dose guide covers each step.

People with a history of pancreatitis, certain thyroid conditions, or serious gastrointestinal disease will have been assessed at the consultation stage; the prescriber checks whether semaglutide is appropriate before treatment begins. Semaglutide is not recommended during pregnancy, while breastfeeding, or if you are trying to conceive. It is not licensed for under-18s.

Reporting side effects and staying in contact with your clinical team

If a side effect concerns you, the right step is always to contact the prescribing service rather than adjusting your dose or stopping without guidance. Both have consequences: unmanaged nausea can lead to poor intake and fatigue; stopping abruptly means you lose the appetite regulation the medicine was providing, often quite suddenly.

For suspected side effects you think others should know about, the MHRA Yellow Card scheme accepts reports from patients directly, not just healthcare professionals. Reporting takes around ten minutes and helps the regulator build an accurate picture of how medicines perform in real-world use. If you have a question about whether a symptom you're experiencing is linked to treatment, our frequently asked questions cover common queries, and our clinical team is available seven days a week through the support page. For a broader look at what treatment involves, our Wegovy overview sets out how the medicine works and who it is intended for. Decisions about suitability and how to manage side effects are made with a prescriber, a free consultation is the starting point if you haven't begun yet.